Known targets — ChEMBL curated mechanism
ABL1BMXBRAFBTKCHRNA4CHRNB2CSNK1EEGFRERBB2F10FLT1FLT3FLT4IGF1RINSRITKJAK3KDRKITOPRM1PARP1PARP2PDGFRBPIK3CDRAF1RETSLC18A2TECTXKdacAdacBdacCftsImrcAmrcBmrdArplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Cysteamine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 2/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.47 |
| ▸ | CA1 | P00915 | 2/20 | 0.47 |
| ▸ | CA2 | P00918 | 2/20 | 0.47 |
| ▸ | CA12 | O43570 | 1/20 | 0.47 |
| ▸ | CA3 | P07451 | 1/20 | 0.47 |
| ▸ | CA6 | P23280 | 1/20 | 0.47 |
| ▸ | CA5A | P35218 | 1/20 | 0.47 |
| ▸ | CA7 | P43166 | 1/20 | 0.47 |
| ▸ | CA9 | Q16790 | 1/20 | 0.47 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | NT5E | P21589 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ethylenediamine SCHEMBL11226382 | 0.90 | ALDH1A1 (0.52) | CYP2C9CYP1A2ALDH1A1CA1CA2 | |
| Ethylenediamine SCHEMBL769088 | 0.90 | ALDH1A1 (0.52) | CYP2C9CYP1A2ALDH1A1CA1CA2 | |
| SCHEMBL11546476 | 0.86 | CYP2C9 (0.49) | CYP2C9CYP1A2ALDH1A1CA1CA2 | |
| Propylamine SCHEMBL6911004 | 0.86 | CYP2C9 (0.49) | CYP2C9CYP1A2ALDH1A1CA1CA2 | |
| SCHEMBL20591829 | 0.86 | ALDH1A1 (0.48) | CYP2C9CYP1A2ALDH1A1CA1CA2 | |
| Monoethanolamine SCHEMBL1274858 | 0.86 | CYP2C9 (0.49) | CYP2C9CYP1A2ALDH1A1CA1CA2 | |
| Putrescine SCHEMBL10842435 | 0.86 | CYP2C9 (0.49) | CYP2C9CYP1A2ALDH1A1CA1CA2 | |
| Ethylamine SCHEMBL3808345 | 0.86 | ALDH1A1 (0.52) | CYP2C9CYP1A2ALDH1A1CA1CA2 | |
| SCHEMBL8981419 | 0.85 | CYP2C9 (0.48) | CYP2C9CYP1A2ALDH1A1CA1CA2 | |
| Hydrazine SCHEMBL8861759 | 0.83 | ALDH1A1 (0.58) | CYP2C9CYP1A2ALDH1A1CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114094166-A | Lithium ion battery non-aqueous electrolyte and lithium ion battery | 北京胜能能源科技有限公司 | 2022-02-25 | — | — | CN | claimed |
| US-20260124306-A1 | NUCLEIC ACID-CONTAINING LIPID NANO-PARTICLE AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2026-05-07 | — | — | US | disclosed |
| US-12551561-B2 | Nucleic acid-containing lipid nano-particle and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2026-02-17 | — | — | US | disclosed |
| US-20250221408-A1 | COMPOSITION | EARTH CORPORATION (JP) | 2025-07-10 | — | — | US | disclosed |
| CN-119114152-A | Free radical generating catalyst, method for producing free radical, method for producing oxidation reaction product, pharmaceutical agent, and agricultural and livestock pharmaceutical agent | 株式会社ACENET | 2024-12-13 | — | — | CN | disclosed |
| EP-4473837-A1 | COMPOSITION | Earth Corporation (JP) | 2024-12-11 | — | — | EP | disclosed |
| CN-118695780-A | Composition and method for producing the same | 阿斯制药株式会社 | 2024-09-24 | — | — | CN | disclosed |
| CN-110769931-B | Free radical generating catalyst, method for producing free radical, method for producing oxidation reaction product, pharmaceutical agent, and agricultural and livestock pharmaceutical agent | 株式会社ACENET | 2024-09-17 | — | — | CN | disclosed |
| CN-118634318-A | Nucleic acid-containing lipid nanoparticles and uses thereof | 武田药品工业株式会社 | 2024-09-13 | — | — | CN | disclosed |
| CN-118593692-A | Nucleic acid-containing lipid nanoparticles and uses thereof | 武田药品工业株式会社 | 2024-09-06 | — | — | CN | disclosed |
| US-20120049136-A1 | CONDUCTIVE POLYMER FILM, ELECTRIC DEVICES AND METHODS FOR MANUFACTURING THE CONDUCTIVE POLYMER FILM | SANYO ELECTRIC CO., LTD. (JP) | 2012-03-01 | — | — | US | disclosed |
| US-20110051319-A1 | CONDUCTING POLYMER MEMBRANE, METHOD OF MANUFACTURING CONDUCTING POLYMER MEMBRANE, AND ELECTRONIC DEVICE | SANYO ELECTRIC CO., LTD. (JP) | 2011-03-03 | — | — | US | disclosed |
| US-20100271757-A1 | SOLID ELECTROLYTIC CAPACITOR AND FABRICATION METHOD THEREOF | SANYO ELECTRIC CO., LTD. (JP) | 2010-10-28 | — | — | US | disclosed |
| US-20100232090-A1 | CONDUCTIVE POLYMER FILM, ELECTRONIC DEVICE, AND METHODS OF PRODUCING THE FILM AND THE DEVICE | SANYO ELECTRIC CO., LTD. (JP) | 2010-09-16 | — | — | US | disclosed |
| US-7399508-B2 | Recording medium | FUJIFILM CORPORATION (JP) | 2008-07-15 | — | — | US | disclosed |
| CN-100398334-C | Recording medium | FUJI PHOTO FILM CO LTD (JP) | 2008-07-02 | — | — | CN | disclosed |
| EP-1481812-B1 | Recording medium | FUJI PHOTO FILM CO LTD (JP) | 2006-12-20 | — | — | EP | disclosed |
| CN-1603131-A | Recording medium | FUJI PHOTO FILM CO LTD (JP) | 2005-04-06 | — | — | CN | disclosed |
| US-20040241347-A1 | Recording medium | FUJI PHOTO FILM CO., LTD. | 2004-12-02 | — | — | US | disclosed |
| EP-1481812-A2 | Recording medium | FUJI PHOTO FILM CO., LTD. (JP) | 2004-12-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250221408-A1 | COMPOSITION | GGPS1, PGGT1B, HBG2 | CYP2C9 1090/4885CYP1A2 92/4885ALDH1A1 1071/4885 |
| US-20260124306-A1 | NUCLEIC ACID-CONTAINING LIPID NANO-PARTICLE AND USE THEREOF | CD4, HAVCR2, CD47 | CYP2C9 3639/4885CYP1A2 4074/4885ALDH1A1 2487/4885 |
| US-12551561-B2 | Nucleic acid-containing lipid nano-particle and use thereof | CD47, PBK, TLR9 | CYP2C9 4318/4885CYP1A2 4731/4885ALDH1A1 3377/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.